Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma.
OBJECTIVE
The study aim was to evaluate progression-free survival (PFS) and overall survival (OS) in patients with metastatic clear cell renal cell carcinoma on sunitinib (SU) and SU-everolimus treatment.


METHODS
After 7 years of enrollment and 9 years of follow-up, 193 consecutively presenting patients (151 men and 42 women) were treated.


RESULTS
A total of 157 patients (81.3%) died and 36 patients (18.7%) survived. Median PFS in 193 SU-treated patients was 14.7 months and OS was 28.8 months. Median PFS was 13.98 months and median OS was 26.67 months in 175 patients treated with SU only or on SU-everolimus.


CONCLUSIONS
The development of SU-induced hypothyroidism, hypertension, neutropenia and edema was a significant predictive and prognostic factor.
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Anna M
AM
Czarnecka
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.|Second Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Paweł
P
Sobczuk
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Jan
J
Korniluk
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.|Second Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.|National Institute of Geriatrics, Rheumatology & Rehabilitation, Warsaw, Poland.
Marta
M
Spychalska
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.|First Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Krzysztof
K
Bogusz
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.|Second Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.|Department of Internal Diseases & Hematology, Military Institute of Medicine, Warsaw, Poland.
Anna
A
Owczarek
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.|Second Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Anna
A
Brodziak
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.|Second Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Dominika
D
Labochka
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.|Second Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Barbara
B
Moszczuk
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Cezary
C
Szczylik
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D003131:Combined Modality Therapy; D000068338:Everolimus / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019233:Retreatment; D012307:Risk Factors; D000077210:Sunitinib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib
EVE; SU; everolimus; prediction; prognosis; renal cancer; sunitinib; survival